Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA
NCT06181136Phase 2Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Dec 2023
- Primary completion
- Jul 2032
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of zafinofusp alfa in mucopolysaccharidosis type III A (6 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoint: Cerebrospinal fluid heparan sulfate concentration at 49 weeks. Started Dec 2023; status: recruiting.
02
Drugs
zafinofusp alfa
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on NCT06181136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181136.